Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/11475
|
| Title: | Improvement in mortality and end-stage renal disease in patients with type 2 diabetes after acute kidney injury who are prescribed dipeptidyl peptidase-4 inhibitors |
| Authors: | Chen, CY;Wu, VC;Lin, CJ;Lin, CS;Pan, CF;Chen, HH;Lin, YF;Huang, TM;Chen, L;Wu, CJ;Wu, VC;Lai, TS;Lin, YF;Tsai, IJ;Lai, CF;Huang, TM;Chu, TS;Chen, YM;Wang, JJ;Chang, YH;Chen, CY;Shiao, CC;Wang, WJ;Lin, JH;Wu, CH;Yeh, YC;Lai, CH;Tseng, LJ;Wu, CJ;Wu, KD;National Taiwan University Study Group on Acute Renal Failure. |
| Contributors: | Institute of Population Health Sciences |
| Abstract: | Objective: To focus on the potential beneficial effects of the pleiotropic effects of dipeptidyl peptidase-4 inhibitors (DPP4is) on attenuating progression of diabetic kidney disease in reducing the long-term effect of the acute kidney injury (AKI) to chronic kidney disease (CKD) transition. Patients and Methods: Data from the National Health Insurance Research Database from January 1, 1999, to July 31, 2011, were analyzed, and patients with diabetes weaning from dialysis-requiring AKI were identified. Cox proportional hazards models and inverse-weighted estimates of the probability of treatment were used to adjust for treatment selection bias. The outcomes were incident end-stage renal disease (ESRD) and mortality, major adverse cardiovascular events, and hospitalized heart failure. Results: Of a total of 6165 patients with diabetes weaning from dialysis-requiring AKI identified, 5635 (91.4%) patients were DPP4i nonusers and 530 (8.6%) patients were DPP4i users. Compared with DPP4i nonusers, DPP4i users had a lower risk of ESRD (hazard ratio, 0.81; 95% CI, 0.70-0.94; P=.04) and all-cause mortality (hazard ratio, 0.28; 95% CI, 0.23-0.34; P<.001) after adjustments for CKD, advanced CKD, and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use. In contrast, the risk of major adverse cardiovascular events and hospitalized heart failure did not differ significantly between groups. Conclusion: Dipeptidyl peptidase-4 inhibitor users had a lower risk of ESRD and mortality than did nonusers among patients with diabetes after weaning from dialysis-requiring AKI. Therefore, a prospective study of AKI to CKD transitions after episodes of AKI is needed to optimally target DPP4i interventions. |
| Date: | 2018-12 |
| Relation: | Mayo Clinic Proceedings. 2018 Dec;93(12):1760-1774. |
| Link to: | http://dx.doi.org/10.1016/j.mayocp.2018.06.023 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0025-6196&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000452006300012 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85055027596 |
| Appears in Collections: | [陳麗光] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| SCP85055027596.pdf | | 695Kb | Adobe PDF | 315 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
